Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Src homology 2 domain containing (SHC) is a proto-oncogene which mediates cell proliferation and carcinogenesis in human carcinomas. Here, the
SHC SH2-domain binding protein 1
(
SHCBP1
) was first established to be up-regulated in human hepatocellular carcinoma (HCC) tissues by array-base comparative genome hybridization (aCGH). Meanwhile, we examine and verify it by quantitative real-time PCR and western blot. Our current data show that
SHCBP1
was up-regulated in HCC tissues. Overexpression of
SHCBP1
could significantly promote HCC cell proliferation, survival and colony formation in HCC cell lines. Furthermore, knockdown of
SHCBP1
induced cell cycle delay and suppressed cell proliferation. Furthermore,
SHCBP1
could regulate the expression of activate extracellular signal-regulated kinase 1/2 (
ERK1
/2) and cyclin D1. Together, our findings indicate that
SHCBP1
may contribute to human hepatocellular carcinoma by promoting cell proliferation and may serve as a molecular target of cancer therapy.
...
PMID:Targeting SHCBP1 inhibits cell proliferation in human hepatocellular carcinoma cells. 2428 56
The SS18-SSX1 fusion gene has been shown to play important roles in the development of synovial sarcoma (SS), but the underlying molecular mechanisms and its downstream target genes are still not clear. Here
SHC SH2-domain binding protein 1
(
SHCBP1
) was identified and validated to be a novel downstream target gene of SS18-SSX1 by using microarray assay, quantitative real-time (qPCR) and western blot. Expression of
SHCBP1
was firstly confirmed in SS cell line and SS tissues. The effects of
SHCBP1
overexpression or knockdown on SS cell proliferation and tumorigenicity were then studied by cell proliferation, DNA replication, colony formation, flow cytometric assays, and its in vivo tumorigenesis was determined in the nude mice. Meanwhile, the related signaling pathways of
SHCBP1
were also examined in SS cells. The results indicated that
SHCBP1
was significantly increased in SS cells and SS tissues compared with adjacent noncancerous tissues. The expression of
SHCBP1
was demonstrated to be positively correlated with the SS18-SSX1 level. Overexpression and ablation of
SHCBP1
promoted and inhibited, respectively, the proliferation and tumorigenicity of SS cells in vitro.
SHCBP1
knockdown also significantly inhibited SS cell growth in nude mice, and lowered the
MAPK
/ERK and PI3K/AKT/mTOR signaling pathways and cyclin D1 expression. Our findings disclose that
SHCBP1
is a novel downstream target gene of SS18-SSX1, and demonstrate that the oncogene SS18-SSX1 promotes tumorigenesis by increasing the expression of
SHCBP1
, which normally acts as a tumor promoting factor.
...
PMID:Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma. 2757 15